4.6 Review

The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway

Journal

ENDOCRINE REVIEWS
Volume 39, Issue 5, Pages 676-700

Publisher

ENDOCRINE SOC
DOI: 10.1210/er.2017-00232

Keywords

-

Funding

  1. INSERM
  2. Toulouse University Hospital (CHU)
  3. ERA-Net for research programs on rare diseases (E-Rare, project NSEuroNet: European Network on Noonan Syndrome and Related Disorders)
  4. DGOS

Ask authors/readers for more resources

Noonan syndrome [NS; Mendelian Inheritance in Men (MIM) #163950] and related syndromes [Noonan syndrome with multiple lentigines (formerly called LEOPARD syndrome; MIM #151100), Noonan-like syndrome with loose anagen hair (MIM #607721), Costello syndrome (MIM #218040), cardio-facio-cutaneous syndrome (MIM #115150), type I neurofibromatosis (MIM #162200), and Legius syndrome (MIM #611431)] are a group of related genetic disorders associated with distinctive facial features, cardiopathies, growth and skeletal abnormalities, developmental delay/mental retardation, and tumor predisposition. NS was clinically described more than 50 years ago, and disease genes have been identified throughout the last 3 decades, providing a molecular basis to better understand their physiopathology and identify targets for therapeutic strategies. Most of these genes encode proteins belonging to or regulating the so-called RAS/MAPK signaling pathway, so these syndromes have been gathered under the name RASopathies. In this review, we provide a clinical overview of RASopathies and an update on their genetics. We then focus on the functional and pathophysiological effects of RASopathycausing mutations and discuss therapeutic perspectives and future directions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available